Amla on Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion

• Status: Recruiting
• Trial end date: 2021-12-30
• Target enrollment: 0
• Participant gender: All

Summary

Amla has demonstrated promising effects in the treatment of obesity, dyslipidemia, hypertension, insulin secretion, among others. The above mentioned findings show that Amla has an excellent potential for the prevention and treatment of metabolic syndrome.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Guadalajara
• Treatments: Insulin; Insulin, Globin Zinc; Magnesium Oxide

Criteria

Inclusion criteria:

• Diagnosed Metabolic Syndrome according to the IDF criteria:

• - - Waist circumference: ≥80 cm (women) ≥90 cm (men), plus two or more of the following:

• - - Fasting glucose ≥ 100 mg/dL to <126 mg/dL.

• - - Triglycerides ≥150 mg/dL to <499 mg/dL

• - - HDL-C: Men ≤40 mg/dL, women ≤50 mg/dL

• - - Systolic blood pressure ≥130 to <140 mmHg

• - - Diastolic blood pressure ≥85 to <89 mmHg

• Body Mass Index between 25 and 34.9 kg/m²

• No pharmacological treatment for Metabolic Syndrome

Exclusion Criteria:

• Pregnancy or breast-feeding

• Known allergy to Amla or placebo

• History of hepatic, kidney or thyroid disease

• Drugs or supplements consumption with proven properties that modify the behavior of the Metabolic Syndrome